The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Melphalan + Bortezomib (MelVel) and Mel + Vel + Thalidomide (MelVelThal) as a conditioning regimen for autologous peripheral blood stem cell transplantation (ASCT) in patients (pts) with advanced multiple myeloma (MM): An updated analysis of 2 phase I/II studies.
 
Shijia Zhang
No Relationships to Disclose
 
Noa Biran
No Relationships to Disclose
 
David Samuel DiCapua Siegel
Stock and Other Ownership Interests - COTA
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Takeda
 
Michele Donato
No Relationships to Disclose
 
David H. Vesole
Stock and Other Ownership Interests - Amgen
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen/Onyx; Celgene; Novartis; Takeda
Speakers' Bureau - Amgen/Onyx; Celgene; Novartis; Takeda
Travel, Accommodations, Expenses - Celgene; Novartis; Onyx; Takeda
 
Andrew Pecora
No Relationships to Disclose
 
Joshua Ryan Richter
Consulting or Advisory Role - Amgen; Celgene; Takeda
Speakers' Bureau - Amgen; Celgene; Janssen; Novartis; Takeda
 
Alan P. Skarbnik
Consulting or Advisory Role - Pharmacyclics
Speakers' Bureau - Genentech; Gilead Sciences; Seagen
 
Andre Goy
Honoraria - Acerta Pharma; Celgene; Pharmacyclics; Takeda
Consulting or Advisory Role - Acerta Pharma; Celgene; Infinity Pharmaceuticals; Pharmacyclics; Takeda
Speakers' Bureau - Pharmacyclics; Takeda
Research Funding - Clinical Trials Through Institution
 
Stuart L. Goldberg
Employment - COTA
Leadership - COTA
Stock and Other Ownership Interests - COTA
Honoraria - Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Astellas Pharma; Bristol-Myers Squibb; Celator; Celgene; Cyclacel; Novartis; Pfizer
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Tatyana A. Feldman
Leadership - Novartis
Speakers' Bureau - Celgene; Pharmacyclics; Seagen
 
Emily Brown
No Relationships to Disclose
 
Kathryn Buttner
No Relationships to Disclose
 
Marie DelFavero
No Relationships to Disclose
 
Sung H. Hong
No Relationships to Disclose
 
Daniel Kim
No Relationships to Disclose
 
Scott D. Rowley
No Relationships to Disclose